CapsoVision, Inc
Close on Oct 19, 2026
- Market cap
- $333.08M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $3.60M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $2.80M | $-0.15 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | $3.90M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $3.50M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $3.30M | – | – |
Press releases
Announcements CapsoVision filed with the SEC
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
Other events · EX-99.1 to Form 8-K
CapsoVision Reports Second Quarter 2026 Financial Results
Material agreement · Results of operations · EX-99.1 to Form 8-K
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CapsoVision Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CapsoVision Announces $14 Million Private Placement Financing
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®
Other events · EX-99.1 to Form 8-K
CapsoVision Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
Other events · EX-99.1 to Form 8-K
CapsoVision Appoints David Garcia as Senior Vice President of Finance
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CapsoVision Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CapsoVision Announces Pricing of Initial Public Offering
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
CapsoVision Announces Closing of Initial Public Offering
Material agreement · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K